Sanofi records win and loss with rare disease drug in Phase III trials
Sanofi’s rare disease drug venglustat has met the primary endpoint in a Phase III trial in Gaucher disease but missed the same achievement in a Phase III trial in Fabry disease. In the LEAP2MONO trial (NCT05222906), venglustat met the primary and three out …